AIM ImmunoTech (AIM)
Market Price (2/14/2026): $1.1 | Market Cap: $2.3 MilSector: Health Care | Industry: Biotechnology
AIM ImmunoTech (AIM)
Market Price (2/14/2026): $1.1Market Cap: $2.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13006% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 870% | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -41%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.5%, Rev Chg QQuarterly Revenue Change % is -26% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 229% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -11541%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -11900% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -606% | ||
| High stock price volatilityVol 12M is 10597% | ||
| Key risksAIM key risks include [1] significant financial viability challenges that create 'going concern' and stock delisting threats, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13006% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 870% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -41%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.5%, Rev Chg QQuarterly Revenue Change % is -26% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 229% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -11541%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -11900% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -606% |
| High stock price volatilityVol 12M is 10597% |
| Key risksAIM key risks include [1] significant financial viability challenges that create 'going concern' and stock delisting threats, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Poor Financial Health and Liquidity Concerns.AIM ImmunoTech reported a net loss of $3.3 million for the third quarter of 2025, with cash, cash equivalents, and marketable investments standing at $2.4 million as of September 30, 2025. The company's monthly cash burn rate was approximately $550,000, and its working capital deficit widened to $9.37 million, highlighting a precarious liquidity position and a short cash runway. This financial instability signals to investors a heightened risk regarding the company's ability to fund ongoing operations and clinical trials without substantial additional financing.
2. Highly Dilutive Rights Offering.The company announced and subsequently commenced a rights offering to raise up to $12 million, if fully subscribed. This offering involves the issuance of units comprising Series G Convertible Preferred Stock and warrants, which are convertible into common stock. Such a financing structure is often perceived as highly dilutive to existing shareholders, as it increases the total number of shares outstanding and can depress the per-share value. The market reacted negatively to the initial announcement of the rights offering, with the stock declining by 5.16% on January 23, 2026. Historically, prior equity offerings by AIM have also been followed by significant share price declines.
Show more
Stock Movement Drivers
Fundamental Drivers
The -47.6% change in AIM stock from 10/31/2025 to 2/14/2026 was primarily driven by a -63.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.10 | 1.10 | -47.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -7.4% |
| P/S Multiple | 13.2 | 20.6 | 56.2% |
| Shares Outstanding (Mil) | 1 | 2 | -63.7% |
| Cumulative Contribution | -47.6% |
Market Drivers
10/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| AIM | -40.4% | |
| Market (SPY) | -0.0% | 16.3% |
| Sector (XLV) | 9.3% | 12.3% |
Fundamental Drivers
The -62.3% change in AIM stock from 7/31/2025 to 2/14/2026 was primarily driven by a -66.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.92 | 1.10 | -62.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -23.3% |
| P/S Multiple | 14.1 | 20.6 | 46.3% |
| Shares Outstanding (Mil) | 1 | 2 | -66.4% |
| Cumulative Contribution | -62.3% |
Market Drivers
7/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| AIM | -57.1% | |
| Market (SPY) | 8.2% | 15.2% |
| Sector (XLV) | 21.4% | 9.8% |
Fundamental Drivers
The 445.4% change in AIM stock from 1/31/2025 to 2/14/2026 was primarily driven by a 3258.0% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.20 | 1.10 | 445.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -41.1% |
| P/S Multiple | 0.6 | 20.6 | 3258.0% |
| Shares Outstanding (Mil) | 1 | 2 | -72.4% |
| Cumulative Contribution | 445.4% |
Market Drivers
1/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| AIM | 519.7% | |
| Market (SPY) | 14.3% | -5.9% |
| Sector (XLV) | 8.8% | -11.9% |
Fundamental Drivers
The 111.7% change in AIM stock from 1/31/2023 to 2/14/2026 was primarily driven by a 1002.8% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.52 | 1.10 | 111.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -16.4% |
| P/S Multiple | 1.9 | 20.6 | 1002.8% |
| Shares Outstanding (Mil) | 0 | 2 | -77.0% |
| Cumulative Contribution | 111.7% |
Market Drivers
1/31/2023 to 2/14/2026| Return | Correlation | |
|---|---|---|
| AIM | 140.6% | |
| Market (SPY) | 74.0% | -3.8% |
| Sector (XLV) | 23.7% | -7.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AIM Return | -49% | -66% | 41% | -55% | 471% | -30% | -56% |
| Peers Return | 4% | -8% | -36% | 29% | 48% | -18% | -4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| AIM Win Rate | 33% | 8% | 58% | 17% | 25% | 50% | |
| Peers Win Rate | 40% | 45% | 37% | 48% | 52% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AIM Max Drawdown | -49% | -67% | 0% | -58% | -52% | -30% | |
| Peers Max Drawdown | -29% | -55% | -65% | -42% | -64% | -27% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ONDS, CLDX, GERN, ATRA, REPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | AIM | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -25.4% | |
| % Gain to Breakeven | 34.1% | |
| Time to Breakeven | 1,628 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -33.9% | |
| % Gain to Breakeven | 51.3% | |
| Time to Breakeven | 1,023 days | 148 days |
| 2018 Correction | ||
| % Loss | -19.8% | |
| % Gain to Breakeven | 24.7% | |
| Time to Breakeven | 24 days | 120 days |
Compare to ONDS, CLDX, GERN, ATRA, REPL
In The Past
AIM ImmunoTech's stock fell null during the 2022 Inflation Shock from a high on 1/1/2021. A null loss requires a null gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AIM ImmunoTech (AIM)
AI Analysis | Feedback
Here are 1-2 brief analogies for AIM ImmunoTech:
- Imagine Moderna before its COVID vaccine breakthrough, but developing immune-modulating drugs for chronic fatigue and cancer.
- An early-stage Vertex Pharmaceuticals, but focused on immune system disorders like ME/CFS and certain cancers with its lead drug candidate.
AI Analysis | Feedback
- Ampligen (rintatolimod): An experimental immune modulator and Toll-like receptor 3 (TLR3) agonist that is AIM ImmunoTech's lead drug candidate, primarily being developed for the treatment of various cancers (including pancreatic cancer) and diseases like Long COVID.
AI Analysis | Feedback
AIM ImmunoTech (symbol: AIM) is a clinical-stage immuno-oncology company focused on the research and development of novel immunotherapies. As such, the company does not currently have "major customers" in the traditional sense of generating substantial revenue from product sales to either other companies or individuals.
The company's primary product candidate, rintatolimab (trade name Ampligen), is currently in clinical trials for various indications. While Ampligen has received limited approval for severe Chronic Fatigue Syndrome (ME/CFS) in Argentina and is available through compassionate use programs in other regions, the commercial sales associated with these activities are minimal and do not constitute a primary revenue stream for AIM ImmunoTech.
Therefore, AIM ImmunoTech does not "primarily sell" to other companies or individuals in a way that generates significant commercial revenue. However, for its extremely limited product sales and distribution activities, the company engages with other companies. These would typically include:
- Distributors: Companies responsible for importing and distributing Ampligen within a specific region (e.g., in Argentina), which then supply healthcare providers or pharmacies. Due to the very limited sales volume and regional nature, specific names of major, publicly traded distributors are not identified by AIM ImmunoTech as significant customers.
- Healthcare Institutions/Providers: In some cases, direct sales might occur to hospitals or specialized clinics participating in compassionate use programs or for specific patient needs, although this is less common for a clinical-stage company managing a global supply chain. These are typically not large, publicly traded entities that would be considered "major customers" of AIM.
It is crucial to reiterate that these entities are not "major customers" for AIM ImmunoTech, as the revenue generated from these limited sales is not significant to the company's overall financial health. The company's financial success is predominantly tied to its research and development milestones, successful clinical trials, and securing future partnerships or regulatory approvals, rather than current commercial product sales.
AI Analysis | Feedback
null
AI Analysis | Feedback
Thomas K. Equels, M.S., J.D. Chief Executive Officer, President & Executive Vice Chairman
Thomas K. Equels has served as the Chief Executive Officer of AIM ImmunoTech Inc. since February 2016, and as a Director on the company's Board of Directors since 2008. He previously held roles within the company as Secretary from 2008 to 2016, General Counsel from 2010 to 2016, and Chief Financial Officer from December 2013 to February 2016. Before joining AIM ImmunoTech, Mr. Equels was the President and Managing Director of the Equels Law Firm in Miami, Florida, where for over 25 years he represented national governments, state governments, and private companies. He also frequently served as a court-appointed receiver tasked with turning around distressed companies.
Robert Dickey IV Chief Financial Officer
Robert Dickey IV brings over 25 years of C-suite financial leadership experience to life science and medical device companies, encompassing both private and public entities. His experience spans from preclinical development to commercial operations across various disease areas and medical technologies.
Peter W. Rodino III, J.D. Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary
Peter W. Rodino III was appointed Executive Director for Governmental Relations and General Counsel in October 2016, and Secretary in November 2016. He previously served as a Director of the company from July 2013 until his resignation to assume his current executive roles. Mr. Rodino possesses extensive legal, financial, and executive experience. His past roles include serving as President of Rodino Consulting LLC and a managing partner at several law firms. Notably, he was also the Chairman and CEO of Crossroads Health Plan, New Jersey's first major Health Maintenance Organization. Additionally, he has experience as an investment executive in the securities industry and has acted as a trustee in numerous complex Chapter 11 corporate reorganizations.
William M. Mitchell, M.D., Ph.D. Chairman of the Board
Dr. William M. Mitchell was appointed Chairman of the Board in February 2016, having served as a Director since July 1998. He is a Professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine and is a board-certified physician. Dr. Mitchell is the inventor or co-inventor of 14 issued U.S. patents. He also served as an independent director of Chronix Biomedical, a genetics-based cancer diagnostic company, until its acquisition by OncoCyte in 2021.
Charles Lapp, M.D. Managing Research Programs (ME/CFS and Long COVID)
Dr. Charles Lapp manages AIM ImmunoTech’s research programs focused on ME/CFS and Long COVID, including the development of protocols and new clinical trials. Prior to joining the company, Dr. Lapp played a crucial role in AIM's long-standing AMP-511 Expanded Access Program for the treatment of ME/CFS and Long COVID, where he founded one of the program's key clinical trial sites, the Hunter-Hopkins Center in Charlotte, North Carolina.
AI Analysis | Feedback
The key risks to AIM ImmunoTech's business are primarily centered on its financial viability, the successful development and regulatory approval of its lead drug candidate, Ampligen, and the potential for shareholder dilution.
- Financial Challenges and Going Concern Risk: AIM ImmunoTech consistently reports substantial net losses and generates minimal revenues, leading to significant financial pressures and a negative stockholders' deficit. The company's heavy reliance on external financing to fund its operations and research and development raises doubts about its ability to continue as a "going concern" for at least the next 12 months. Furthermore, a failure to meet the NYSE American's equity requirements could result in delisting, which would negatively impact the company's liquidity and investor confidence. One analysis estimates an 86% probability of bankruptcy for the company.
- Clinical Trial and Regulatory Risks for Ampligen: The company's future is largely dependent on the successful development and commercialization of Ampligen (rintatolimod), its primary experimental RNA-based therapy. There are no guarantees of future success in its ongoing or planned clinical trials, and any delays or failures would further exacerbate the company's financial strain. Ampligen currently has limited commercial prospects, with approval only in Argentina, and obtaining U.S. regulatory approval would require substantial time and additional clinical data. Early-stage clinical trial results may not be indicative of statistically significant outcomes in larger, pivotal trials.
- Shareholder Dilution: To address its ongoing financial needs and fund its clinical development programs, AIM ImmunoTech frequently needs to raise capital through equity offerings. This practice carries a significant risk of diluting the ownership and value of existing shareholders' investments.
AI Analysis | Feedback
- Slower than anticipated patient enrollment in the pivotal Phase 2/3 AMP-279 clinical trial for metastatic melanoma, potentially delaying the timeline for critical data readout, increasing development costs, and postponing potential market entry.
- Inability to secure funding for the planned Phase 2 AMP-518 clinical trial for Long COVID, which could prevent the company from advancing a key pipeline diversification effort and allow competitors to establish market leadership in this emerging therapeutic area.
AI Analysis | Feedback
Addressable Markets for AIM ImmunoTech's Main Products or Services:
- Ampligen (rintatolimod) for Pancreatic Cancer: The global market for pancreatic cancer is projected to grow from $2.72 billion in 2025 to $13.01 billion by 2037.
- Ampligen (rintatolimod) for Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME/CFS): The global chronic fatigue syndrome treatment market advanced from USD 67.93 billion in 2024 to USD 75.75 billion in 2025 and is projected to reach USD 159.42 billion by 2032, demonstrating a compound annual growth rate (CAGR) of 11.25%. North America dominates this market. Another estimate values the global chronic fatigue syndrome market at USD 13.86 billion in 2025, expected to reach USD 20.03 billion by 2032, growing at a CAGR of 5.4% from 2025 to 2032.
- Ampligen (rintatolimod) for Long COVID (Post-COVID conditions of fatigue): A study indicated a 15-fold increase in ME/CFS incidence post-COVID infection, significantly expanding the potential market for Ampligen. There is a lack of approved treatments for Long COVID, creating a significant market opportunity.
- Alferon N Injection (Interferon alfa) for Genital Warts: null
- Ampligen (rintatolimod) for other cancer types (renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers), Hepatitis B, HIV: null
AI Analysis | Feedback
AIM ImmunoTech (symbol: AIM) is expected to have several key drivers for future revenue growth over the next 2-3 years, primarily centered around its lead investigational drug, Ampligen (rintatolimod). These drivers include:- Advancement and potential approval of Ampligen for pancreatic cancer: AIM ImmunoTech has a stated primary focus on advancing Ampligen through clinical trials for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval. The company has reported positive safety results in the DURIPANC study combining Ampligen with Imfinzi for late-stage metastatic pancreatic cancer, and believes that establishing a clear path to registration in this high-value indication will unlock significant potential.
- Expansion into other oncology indications: Beyond pancreatic cancer, Ampligen is also being developed for the potential treatment of other cancers, including recurrent ovarian cancer (where interim data showed a 45% objective response rate in a study combining Ampligen with Keytruda), renal cell carcinoma, malignant melanoma, non-small cell lung, breast, colorectal, and prostate cancers. Continued progress and potential commercialization in these areas could contribute to future revenue.
- Development and commercialization for Long COVID: AIM ImmunoTech has secured a European patent for compositions containing Ampligen for the treatment of Long COVID. This strengthens their intellectual property portfolio and provides additional validation of Ampligen's potential as a broad-spectrum immunotherapy. Successful clinical trials (such as the AMP-518 Phase 2 study which reported positive topline results regarding a reduction in post-COVID fatigue) and subsequent commercialization in Europe or other markets for Long COVID could represent a new revenue stream.
- Strategic Partnerships and Collaborations: The company is actively facilitating potential partnerships, including with big pharma, to advance its clinical strategy and leverage commercialization opportunities. Collaborations, such as those with AstraZeneca (for pancreatic cancer) and Merck (for advanced ovarian cancer), which partially fund some trials, are crucial for accelerating development and future market access, thereby driving revenue growth through licensing agreements, milestone payments, or co-commercialization efforts.
- New indications and intellectual property expansion: AIM ImmunoTech continues to explore and secure patents for Ampligen in additional indications, such as a U.S. patent for the treatment of endometriosis and plans to conduct a clinical study combining Ampligen with AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza. While these may be longer-term drivers, successful development and commercialization in these newer areas would diversify and expand future revenue sources.
AI Analysis | Feedback
Share Repurchases
No information available regarding share repurchases made or authorized by AIM ImmunoTech within the last 3-5 years.
Share Issuance
- In July 2025, AIM ImmunoTech completed a public offering of 2,000,000 shares of common stock and accompanying warrants, raising approximately $8.0 million in gross proceeds.
- In October 2025, the company launched an at-the-market (ATM) offering to sell up to $2,288,760 of common stock.
- A 1-for-100 reverse stock split was effected on June 12, 2025, to increase the per-share market price and regain compliance with NYSE American's listing qualifications.
Inbound Investments
- The primary form of inbound investment has been through public offerings, such as the $8.0 million raised in July 2025 through the issuance of common stock and warrants.
- An at-the-market offering was initiated in October 2025 to raise up to $2,288,760 in capital.
Outbound Investments
No information available regarding significant outbound investments made by AIM ImmunoTech within the last 3-5 years.
Capital Expenditures
- Capital expenditures for AIM ImmunoTech were reported as -$18,000 in the last 12 months leading up to June 2025.
- Annual capital expenditures were approximately -$0.02 million for fiscal year 2024, none for 2023, and -$0.09 million for 2022.
- The company is focused on optimizing its manufacturing process, which is anticipated to result in $2 million in savings and reduced per-batch production costs.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AIM ImmunoTech Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.21 |
| Mkt Cap | 0.9 |
| Rev LTM | 14 |
| Op Inc LTM | -53 |
| FCF LTM | -101 |
| FCF 3Y Avg | -134 |
| CFO LTM | -101 |
| CFO 3Y Avg | -133 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 51.3% |
| Rev Chg 3Y Avg | 195.1% |
| Rev Chg Q | -25.7% |
| QoQ Delta Rev Chg LTM | -7.4% |
| Op Mgn LTM | -176.1% |
| Op Mgn 3Y Avg | -4,896.5% |
| QoQ Delta Op Mgn LTM | 13.1% |
| CFO/Rev LTM | -137.9% |
| CFO/Rev 3Y Avg | -3,565.5% |
| FCF/Rev LTM | -140.2% |
| FCF/Rev 3Y Avg | -3,610.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 20.6 |
| P/EBIT | -4.2 |
| P/E | -4.6 |
| P/CFO | -5.5 |
| Total Yield | -11.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -25.1% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -7.1% |
| 3M Rtn | -10.8% |
| 6M Rtn | 2.1% |
| 12M Rtn | -17.1% |
| 3Y Rtn | -42.5% |
| 1M Excs Rtn | -5.3% |
| 3M Excs Rtn | -8.4% |
| 6M Excs Rtn | -2.6% |
| 12M Excs Rtn | -31.7% |
| 3Y Excs Rtn | -111.8% |
Price Behavior
| Market Price | $1.25 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/12/1996 | |
| Distance from 52W High | -87.7% | |
| 50 Days | 200 Days | |
| DMA Price | $1.26 | $2.63 |
| DMA Trend | down | down |
| Distance from DMA | -0.5% | -52.5% |
| 3M | 1YR | |
| Volatility | 156.2% | 11,866.1% |
| Downside Capture | 295.15 | 411.43 |
| Upside Capture | 204.84 | 654.09 |
| Correlation (SPY) | 15.5% | -4.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.98 | 2.92 | 3.28 | 2.11 | -25.47 | -13.43 |
| Up Beta | 2.11 | 3.34 | 1.22 | 1.58 | 0.10 | 0.52 |
| Down Beta | 6.32 | 5.87 | 5.89 | 4.13 | -8.67 | -10.20 |
| Up Capture | 240% | -67% | 56% | -14% | -8% | 1% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 17 | 26 | 54 | 83 | 308 |
| Down Capture | 266% | 268% | 348% | 235% | -992% | -123% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 7 | 20 | 30 | 63 | 110 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIM | |
|---|---|---|---|---|
| AIM | -92.2% | 125.9% | -1.85 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 17.6% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 21.0% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | 3.0% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | -7.0% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 11.2% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 7.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIM | |
|---|---|---|---|---|
| AIM | -66.0% | 86.5% | -0.89 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 11.9% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 17.6% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 4.5% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 0.4% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 11.5% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 10.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIM | |
|---|---|---|---|---|
| AIM | -57.9% | 112.9% | -0.32 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 2.6% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 0.4% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 3.9% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | -6.6% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | -2.8% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 0.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/16/2020 | 1.2% | -21.5% | 3.6% |
| SUMMARY STATS | |||
| # Positive | 1 | 0 | 1 |
| # Negative | 0 | 1 | 0 |
| Median Positive | 1.2% | 3.6% | |
| Median Negative | -21.5% | ||
| Max Positive | 1.2% | 3.6% | |
| Max Negative | -21.5% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/17/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Equels, Thomas K | CEO & President | Direct | Buy | 6162025 | 7.70 | 107 | 824 | 299,298 | Form |
| 2 | Equels, Thomas K | CEO & President | Direct | Buy | 6132025 | 8.70 | 103 | 896 | 336,472 | Form |
| 3 | Mitchell, William M | Direct | Buy | 4232025 | 0.03 | 196,851 | 5,000 | 13,252 | Form | |
| 4 | Equels, Thomas K | CEO & President | Direct | Buy | 4232025 | 0.03 | 1,968,504 | 50,000 | 98,235 | Form |
| 5 | Kellner, Ted D | Direct | Buy | 4232025 | 0.03 | 1,968,504 | 50,000 | 50,025 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.